Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2015 | Original Article - Clinical Oncology

Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer

Authors: Fei Fei, Xu Guo, Yibing Chen, Xiaonan Liu, Jianfei Tu, Jinliang Xing, Zhinan Chen, Jiansong Ji, Xianli He

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2015

Abstract

Purpose

Previous studies have demonstrated that monocarboxylate transporters (MCTs) play important roles in the development and progression of many cancers. The purpose of this study was to assess the effects of single-nucleotide polymorphisms (SNPs) of MCT genes on prognosis of colorectal cancer (CRC) patients.

Patients and methods

Nine functional SNPs in three MCT genes (MCT1, MCT2 and MCT4) were selected and genotyped using Sequenom iPLEX genotyping system in 697 Chinese CRC patients receiving surgery. Multivariate Cox proportional hazards model and Kaplan–Meier curve were used for the prognostic analysis.

Results

One SNP (MCT1: rs1049434/exon) was significantly associated with overall survival of CRC patients (HR 0.74; P = 0.046). Two other SNPs (MCT1: rs60844753/5′ near gene and MCT2: rs995343/intron) exhibited associations with recurrence-free survival of CRC patients (HR 0.67; P = 0.078 and HR 0.74; P = 0.036, respectively). Our study also showed that MCT1 rs1049434, rs60844753 and MCT2 rs995343 SNPs had a cumulative effect on CRC recurrence-free survival (P for trend 0.011). Those who carrying three unfavorable genotypes (WW for all SNPs) had a 2.06-fold increased risk of recurrence compared with patients carrying no unfavorable genotypes (P = 0.016). Moreover, we found that patients carrying no <2 risk genotypes showed significant OS and RFS benefits from adjuvant chemotherapy.

Conclusions

Our findings suggest that SNPs in MCT1 and MCT2 genes may affect clinical outcomes and can be used to predict the response to adjuvant chemotherapy in CRC patients who received surgical treatment once validated in future study.

Boidot R et al (2012) Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res 72:939–948. doi:10.1158/0008-5472.CAN-11-2474 CrossRefPubMed

Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW (1999) Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J 341(Pt 3):529–535CrossRefPubMedCentralPubMed

Cupeiro R, Benito PJ, Maffulli N, Calderon FJ, Gonzalez-Lamuno D (2010) MCT1 genetic polymorphism influence in high intensity circuit training: a pilot study. J Sci Med Sport 13:526–530. doi:10.1016/j.jsams.2009.07.004 CrossRefPubMed

Cupeiro R, Gonzalez-Lamuno D, Amigo T, Peinado AB, Ruiz JR, Ortega FB, Benito PJ (2012) Influence of the MCT1-T1470A polymorphism (rs1049434) on blood lactate accumulation during different circuit weight trainings in men and women. J Sci Med Sport 15:541–547. doi:10.1016/j.jsams.2012.03.009 CrossRefPubMed

Diers AR, Broniowska KA, Chang CF, Hogg N (2012) Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. Biochem J 444:561–571. doi:10.1042/BJ20120294 CrossRefPubMed

Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S (2000) The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 350(Pt 1):219–227CrossRefPubMedCentralPubMed

Dufau I et al (2012) Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer 12:15. doi:10.1186/1471-2407-12-15 CrossRefPubMedCentralPubMed

Elf SE, Chen J (2014) Targeting glucose metabolism in patients with cancer. Cancer 120:774–780. doi:10.1002/cncr.28501 CrossRefPubMed

Gerlinger M et al (2012) Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol 227:146–156. doi:10.1002/path.4006 CrossRefPubMedCentralPubMed

Gullino PM, Clark SH, Grantham FH (1964) The interstitial fluid of solid tumors. Cancer Res 24:780–797PubMed

Halestrap AP (2013) The SLC16 gene family–structure, role and regulation in health and disease. Mol Aspects Med 34:337–349. doi:10.1016/j.mam.2012.05.003 CrossRefPubMed

Halestrap AP, Meredith D (2004) The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch 447:619–628. doi:10.1007/s00424-003-1067-2 CrossRefPubMed

Halestrap AP, Price NT (1999) The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343(Pt 2):281–299CrossRefPubMedCentralPubMed

Izumi H et al (2003) Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 29:541–549CrossRefPubMed

Izumi H et al (2011) Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 102:1007–1013. doi:10.1111/j.1349-7006.2011.01908.x CrossRefPubMed

Lean CB, Lee EJ (2009) Genetic variations in the MCT1 (SLC16A1) gene in the Chinese population of Singapore. Drug Metab Pharmacokinet 24:469–474CrossRefPubMed

Lee I, Lee SJ, Kang WK, Park C (2012) Inhibition of monocarboxylate transporter 2 induces senescence-associated mitochondrial dysfunction and suppresses progression of colorectal malignancies in vivo. Mol Cancer Ther 11:2342–2351. doi:10.1158/1535-7163.MCT-12-0488 CrossRefPubMed

Li Q, Du J, Guan P, Du J, Qu CF, Dai M (2012) Estimation and prediction of incidence, mortality and prevalence on liver cancer, in 2008, China. Zhonghua Liu Xing Bing Xue Za Zhi 33:554–557PubMed

Manning Fox JE, Meredith D, Halestrap AP (2000) Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol 529(Pt 2):285–293PubMedCentralPubMed

Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361:2449–2460. doi:10.1056/NEJMra0804588 CrossRefPubMedCentralPubMed

Michaelidou K, Tzovaras A, Missitzis I, Ardavanis A, Scorilas A (2013) The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression. Int J Oncol 42:1770–1777. doi:10.3892/ijo.2013.1860 PubMed

Miranda-Goncalves V et al (2013) Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro-oncology 15:172–188. doi:10.1093/neuonc/nos298 CrossRefPubMedCentralPubMed

Nakayama Y, Torigoe T, Inoue Y, Minagawa N, Izumi H, Kohno K, Yamaguchi K (2012) Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer. Exp Ther Med 3:25–30. doi:10.3892/etm.2011.361 PubMedCentralPubMed

Pertega-Gomes N, Baltazar F (2014) Lactate transporters in the context of prostate cancer metabolism: What do we know? Int J Mol Sci 15:18333–18348. doi:10.3390/ijms151018333 CrossRefPubMedCentralPubMed

Pertega-Gomes N et al (2011) Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 11:312. doi:10.1186/1471-2407-11-312 CrossRefPubMedCentralPubMed

Pertega-Gomes N, Vizcaino JR, Attig J, Jurmeister S, Lopes C, Baltazar F (2014) A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer 14:352. doi:10.1186/1471-2407-14-352 CrossRefPubMedCentralPubMed

Pinheiro C et al (2008) Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch Int J Pathol 452:139–146. doi:10.1007/s00428-007-0558-5 CrossRef

Pinheiro C et al (2010) Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 56:860–867. doi:10.1111/j.1365-2559.2010.03560.x CrossRefPubMed

Pinheiro C et al (2011) GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 26:1279–1286PubMed

Ritzhaupt A, Ellis A, Hosie KB, Shirazi-Beechey SP (1998) The characterization of butyrate transport across pig and human colonic luminal membrane. J Physiol 507(Pt 3):819–830CrossRefPubMedCentralPubMed

Sanita P et al (2014) Tumor–stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer 14:154. doi:10.1186/1471-2407-14-154 CrossRefPubMedCentralPubMed

Shastry BS (2009) SNPs: impact on gene function and phenotype. Methods Mol Biol 578:3–22. doi:10.1007/978-1-60327-411-1_1 CrossRefPubMed

Su J, Chen X, Kanekura T (2009) A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett 273:140–147. doi:10.1016/j.canlet.2008.07.034 CrossRefPubMed

Ulrich CM, Robien K, McLeod HL (2003) Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3:912–920. doi:10.1038/nrc1233 CrossRefPubMed

Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O (2011) Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 71:2550–2560. doi:10.1158/0008-5472.CAN-10-2828 CrossRefPubMed

Zhu J et al (2014) Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients. PLoS One 9:e87904. doi:10.1371/journal.pone.0087904 CrossRefPubMedCentralPubMed

Title: Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer
Authors: Fei Fei
Xu Guo
Yibing Chen
Xiaonan Liu
Jianfei Tu
Jinliang Xing
Zhinan Chen
Jiansong Ji
Xianli He
Publication date: 01-06-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1877-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer

Abstract

Purpose

Patients and methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2015

Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation

The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution

Differential diagnosis between metastatic and non-metastatic lymph nodes using DW-MRI: a meta-analysis of diagnostic accuracy studies

Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer

The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model

BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page